Discovery of XL888: A novel tropane-derived small molecule inhibitor of HSP90

被引:55
作者
Bussenius, Joerg [1 ]
Blazey, Charles M. [1 ]
Aay, Naing [1 ]
Anand, Neel K. [1 ]
Arcalas, Arlyn [1 ]
Baik, TaeGon [1 ]
Bowles, Owen J. [1 ]
Buhr, Chris A. [1 ]
Costanzo, Simona [1 ]
Curtis, Jeffrey K. [1 ]
DeFina, Steven C. [1 ]
Dubenko, Larisa [1 ]
Heuer, Timothy S. [1 ]
Huang, Ping [1 ]
Jaeger, Christopher [1 ]
Joshi, Anagha [1 ]
Kennedy, Abigail R. [1 ]
Kim, Angie I. [1 ]
Lara, Katherine [1 ]
Lee, Jae [1 ]
Li, Jonathan [1 ]
Lougheed, Julie C. [1 ]
Ma, Sunghoon [1 ]
Malek, Shiva [1 ]
Manalo, Jean-Claire L. [1 ]
Martini, Jean-Francois [1 ]
McGrath, Garth [1 ]
Nicoll, Monique [1 ]
Nuss, John M. [1 ]
Pack, Michael [1 ]
Peto, Csaba J. [1 ]
Tsang, Tsze H. [1 ]
Wang, Longcheng [1 ]
Womble, Scott W. [1 ]
Yakes, Michael [1 ]
Zhang, Wentao [1 ]
Rice, Kenneth D. [1 ]
机构
[1] Exelixis Inc, San Francisco, CA 94080 USA
关键词
HSP90; Inhibitor; XL888; Tropane; Cancer; SHOCK-PROTEIN; 90; HEAT-SHOCK-PROTEIN-90; INHIBITORS; KINASE DOMAIN; CHAPERONE; GELDANAMYCIN; BIIB021; POTENT; RAF;
D O I
10.1016/j.bmcl.2012.07.052
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
With structural guidance, tropane-derived HTS hits were modified to optimize for HSP90 inhibition and a desirable in vivo profile. Through an iterative SAR development process 12i (XL888) was discovered and shown to reduce HSP90 client protein content in PD studies. Furthermore, efficacy experiments performed in a NCI-N87 mouse xenograft model demonstrated tumor regression in some dosing regimens. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5396 / 5404
页数:9
相关论文
共 38 条
[1]  
An WG, 2000, CELL GROWTH DIFFER, V11, P355
[2]  
Baichwal V.R., 2011, AACR 102 ANN M ORL F, P2
[3]   Heat Shock Protein 90 as a Drug Target: Some Like It Hot [J].
Banerji, Udai .
CLINICAL CANCER RESEARCH, 2009, 15 (01) :9-14
[4]   Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer [J].
Bao, Rudi ;
Lai, Cheng-Jung ;
Wang, Da-Gong ;
Qu, Hui ;
Yin, Ling ;
Zifcak, Brian ;
Tao, Xu ;
Wang, Jing ;
Atoyan, Ruzanna ;
Samson, Maria ;
Forrester, Jeffrey ;
Xu, Guang-Xin ;
DellaRocca, Steven ;
Borek, Mylissa ;
Zhai, Hai-Xiao ;
Cai, Xiong ;
Qian, Changgeng .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12) :3296-3306
[5]   Heat Shock Protein 90: Inhibitors in Clinical Trials [J].
Biamonte, Marco A. ;
Van de Water, Ryan ;
Arndt, Joseph W. ;
Scannevin, Robert H. ;
Perret, Daniel ;
Lee, Wen-Cherng .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (01) :3-17
[6]   Molecular chaperones and protein quality control [J].
Bukau, Bernd ;
Weissman, Jonathan ;
Horwich, Arthur .
CELL, 2006, 125 (03) :443-451
[7]   Hsp90: the vulnerable chaperone [J].
Chiosis, G ;
Vilenchik, M ;
Kim, J ;
Solit, D .
DRUG DISCOVERY TODAY, 2004, 9 (20) :881-888
[8]   The 90-kDa molecular chaperone family:: Structure, function, and clinical applications.: A comprehensive review [J].
Csermely, P ;
Schnaider, T ;
Soti, C ;
Prohászka, Z ;
Nardai, G .
PHARMACOLOGY & THERAPEUTICS, 1998, 79 (02) :129-168
[9]   Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin [J].
Dias, SD ;
Friedlos, F ;
Light, Y ;
Springer, C ;
Workman, P ;
Marais, R .
CANCER RESEARCH, 2005, 65 (23) :10686-10691
[10]   Experimental investigation of protein folding and misfolding [J].
Dobson, CM .
METHODS, 2004, 34 (01) :4-14